BioPharma Credit PLC is a UK-based closed-ended investment trust that operates as a specialist debt investor for the global life sciences industry. The company's primary objective is to generate long-term shareholder returns, predominantly through sustainable income distributions, by providing flexible debt capital to biopharmaceutical and healthcare companies. Its portfolio consists of senior secured loans, unsecured debt, royalty investments, and credit-linked notes. These debt assets are typically secured by royalties or other predictable cash flows derived from the sales of approved life sciences products, mitigating the clinical and regulatory risks associated with early-stage drug development.
The trust is externally managed by Pharmakon Advisors, LP, a specialized investment manager with extensive experience in healthcare finance. BioPharma Credit's revenue is generated entirely from interest income, royalty payments, and fees associated with its lending activities. Key investments have included senior secured loans to companies such as BioCryst Pharmaceuticals, Collegium Pharmaceutical, ImmunoGen, and Evolus. By addressing the substantial capital needs of the biopharmaceutical sector—which has historically relied heavily on equity financing—BioPharma Credit occupies a distinctive niche as a dedicated, large-scale provider of debt capital. The company is listed on the London Stock Exchange and distributes its income to shareholders through regular dividends.
